Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q9NYS0

UPID:
KBRS1_HUMAN

ALTERNATIVE NAMES:
I-kappa-B-interacting Ras-like protein 1

ALTERNATIVE UPACC:
Q9NYS0; Q96K18

BACKGROUND:
The NF-kappa-B inhibitor-interacting Ras-like protein 1, alternatively named I-kappa-B-interacting Ras-like protein 1, is a potent regulator of NF-kappa-B activity. It prevents the degradation of the NF-kappa-B inhibitor beta (NFKBIB) against most signals, explaining NFKBIB's enhanced degradation resistance. The protein potentially operates by blocking NFKBIB phosphorylation and ensuring the cytoplasmic retention of the p65/RELA NF-kappa-B subunit. The role of this protein as a GTPase is intriguing, with both its GTP- and GDP-bound states inhibiting NFKBIB phosphorylation.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of NF-kappa-B inhibitor-interacting Ras-like protein 1 could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.